Two pivotal studies of biosimilar epoetin alfa (Retacrit) versus its reference (Epogen) in patients undergoing hemodialysis have shown that the biosimilar and the originator have comparable safety and efficacy. In the phase 3b PIEDA (Phase 3b Investigation of Erythropoietin Drugs Using a Specified Dosing Algorithm) study, investigators sought to further investigate how switching from the reference to the biosimilar affects maintenance of hemoglobin levels when using an erythropoiesis-stimulating agent dosing algorithm.
Two pivotal studies of biosimilar epoetin alfa (Retacrit) versus its reference (Epogen) in patients undergoing hemodialysis have shown that the biosimilar and the originator have comparable safety and efficacy. In the phase 3b PIEDA (Phase 3b Investigation of Erythropoietin Drugs Using a Specified Dosing Algorithm) study, investigators sought to further investigate how switching from the reference to the biosimilar affects maintenance of hemoglobin levels when using an erythropoiesis-stimulating agent (ESA) dosing algorithm.
Click to read more about Retacrit.
The 24-week, open-label PIEDA study was conducted in 418 patients with anemia and chronic kidney disease at 46 Fresenius Medical Care North America (FMCNA) dialysis centers. The investigators used a computerized dosing algorithm that was originally developed for the reference program and is used in real-world practice in the FMCNA dialysis centers. The study’s primary endpoint was the proportion of the time that patients’ hemoglobin levels were 9 g/dL to 11 g/dL during the final 8 weeks of the study.
Patients were randomized to either continue treatment with the reference product (n = 206) or switch to the biosimilar (n = 212), and were treated for 24 weeks. Throughout the treatment period, the dose of epoetin alfa was adjusted using the algorithm, though the algorithm’s dose recommendation could be overridden at the provider’s discretion.
Data from 178 patients in the switch arm and 173 patients in the reference arm were included in the primary endpoint analysis. The estimated proportion of time that patients had hemoglobin levels in the target range was 61.9% (95% CI, 57.5%-66.2%) in the switch arm and 63.3% (95% CI, 58.7%-67.7%) in the reference arm. The estimated difference in proportions between the arms was —1.4% (95% CI, –7.6%-4.9%). The lower bound of the 95% CI was greater than the prespecified noninferiority margin of –12.5%, demonstrating noninferiority of switching to the biosimilar versus remaining on the reference.
Analysis of the change from baseline in weekly mean ESA doses over the final 8 weeks was based on 180 patients in the switch arm and 174 patients in the reference arm. The least squares mean change from baseline was —1861.8 (standard deviation [SD], 563.5) units per week for the switch arm and –799.8 (SD, 573.1) units per week for the reference arm, a difference that was not statistically significant.
In the final 8 weeks of treatment, the majority of patients had hemoglobin levels in the range of 10 g/dL to 11 g/dL in both the switch arm (56.7%) and the reference arm (53.2%) arm.
A total of 418 patients (61.5%) reported at least 1 treatment-emergent adverse event (AE). Of these patients, 135 were in the switch arm and 122 were in the reference arm. The most frequently reported AEs were dyspnea, falls, and nausea. The proportion of patients who had serious AEs was 31.1% in each arm. Twelve patients in each arm died during the study period, while 68 patients in the switch arm and 63 patients in the reference arm were hospitalized. There were no notable changes from baseline in laboratory parameters and vital signs between arms.
The authors concluded that switching to biosimilar epoetin alfa was noninferior to continued treatment with the reference in maintaining hemoglobin levels in patients with anemia and chronic kidney disease who are managed on hemodialysis when both treatments are dosed using an algorithm.
Reference
Thadhani R, Guilatco R, Hymes J, Maddux FW, Ahuja A. Switching from epoetin alfa (Epogen) to epoetin alfa-epbs (Retacrit) using a dosing algorithm: a randomized, non-inferiority study in adults on hemodialysis. Am J Nephrol. 2018;48(3): 214-224. doi: 10.1159/000492621.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.